ClinicalTrials.gg
CompletedNCT01513902Updated Jul 4, 2016Results posted

Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)

A Phase 1 interventional study of CP-690,550 and CP-690,550 in Juvenile Idiopathic Arthritis, sponsored by Pfizer. Completed at 10 sites in 4 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-07-04.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.

Started
2013
with 1 other
Phase 1
Only one
of the 10
Registered
7th of 10
by date

Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is one of 2 that started in 2013, is the only one in phase 1, and was the 7th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by Pfizer, or all of them as a file.
02

Study summary

Phase 1 study to describe pharmacokinetics of CP-690,550 in pediatric patients 2 to less than 18 years of age with Juvenile Idiopathic Rheumatoid Arthritis (JIA).

Read the detailed description

This is an open-label, non-randomized, multi-center, oral CP-690,550, multiple-dose (twice daily for 5 days [except Day 5 when only morning dose will be given]) study in pediatric subjects with JIA aged from 2 to less than 18 years. Baseline visit will occur within 1 month of the completion of the Screening Visit. The study will consist of three cohorts based on the age of the subjects, Cohort 3: 2 to less than 6 years, Cohort 2: 6 to less than 12 years and Cohort 1: 12 to less than 18 years. In each cohort, at least 8 pediatric subjects with JIA will participate in the study ensuring a total number of at least 24 pediatric evaluable subjects completing the PK period.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Keywords

  • Arthritis
  • Pediatric
  • Tofacitinib
  • JIA
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pediatric patients with JIA aged from 2 to less than 18 years with active JIA (extended oligoarthritis, polyarthritis rheumatoid factor positive or negative, psoriatic arthritis, enthesitis related arthritis), in 5 or more joints (using American College Rheumatology definition of active joint) at the time of the first study drug administration.
  2. For subjects receiving MTX treatment, minimum duration of therapy is 4 months and dose stable for at least 6 weeks prior to first dose of study drug. MTX may be administered either orally or parenterally at doses not to exceed 20 mg/wk or 15 mg/m2/week.
  3. A negative QuantiFERON-TB Gold In-Tube test performed within the 3 months prior to screening. A negative PPD test can be substituted for the QuantiFERON-TB Gold In-Tube test only if the central laboratory is unable to perform the test or cannot determine the results to be positive or negative and the Pfizer medical monitor approves it, on a case-by-case basis.

Exclusion criteria

Exclusion Criteria:

  1. Systemic JIA, persistent oligoarthritis, undifferentiated arthritis.
  2. Current or recent history of uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, or neurological disease.
  3. History of any other rheumatic disease.
  4. Infections:

    1. Latent or active TB or any history of previous TB.
    2. Chronic infections.
    3. Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 6 months prior to the first dose of study drug.
    4. Any treated infections within 2 weeks of Baseline visit.
    5. A subject known to be infected with (HIV), or virus.
    6. History of infected joint prosthesis with prosthesis still in situ.
  5. History of recurrent (more than one episode) herpes zoster or disseminated (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.
  6. The biologic agents and DMARDs are disallowed at any time during this study. If a subject needs to be treated with one of these agents, the subject should be discontinued from the study.
  7. Subjects who have been vaccinated with live or attenuated vaccines within the 6 weeks prior to the first dose of study medication or is to be vaccinated with these vaccines at any time during treatment or within 6 weeks following discontinuation of study drug.
  8. Subjects with a or with a history of malignancy with the exception of adequately treated or excised non- basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Ages 12 to less than 18

    Drug: CP-690,550

  • Experimental
    Cohort 2

    Ages 6 to less than 12

    Drug: CP-690,550

  • Experimental
    Corhort 3

    Ages 2 to less than 6

    Drug: CP-690,550

Interventions

  • CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5

    Also known as: Tofacitinib

  • CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5

    Also known as: Tofacitinib

  • CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing \<30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5

    Also known as: Tofacitinib

06

What researchers measure

Primary outcomes

  1. Apparent Oral Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is also influenced by the fraction of the dose absorbed. Clearance was estimated by non compartmental analysis (NCA) of PK data. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing the given oral dose by AUCtau. AUCtau is the area under the plasma concentration time-curve from time zero to end of dosing interval.

    Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose

  2. Number of Participants With Treatment-Emergent Adverse Events (AEs) All Causalities

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs included both serious and non-serious AEs.

    Time frame: Baseline up to 28 days after the last dose of study drug (Day 5)

  3. Number of Participants With Laboratory Test Abnormalities

    Participants with laboratory test abnormalities of potential clinical concern without regard to baseline abnormality were reported. Criteria: Hematology(hemoglobin,hematocrit,red blood cell\[RBC\] count:\<0.8\*lower limit of normal \[LLN\], platelets:\<0.5\*LLN/greater than \[\>\]1.75\*upper limit of normal\[ULN\], white blood cell \[WBC\] count:\<0.6\*LLN\>\</0\>1.5\*ULN, lymphocytes, total neutrophils:\<0.8\*LLN or \>1.2\*ULN, basophils, eosinophil, monocytes:\>1.2\*ULN); Liver Function (total bilirubin: \>1.5\*ULN, aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:\>3.0\*ULN, total protein, albumin:\<0.8\*LLN or \>1.2\*ULN);Renal Function (blood urea nitrogen, creatinine:\>1.3\*ULN, uric acid:\>1.2\*ULN); Electrolytes (sodium:\<0.95\*LLN or \>1.05\*ULN,potassium,chloride,calcium,bicarbonate:\<0.9\*LLN or \>1.1\*ULN);Clinical chemistry (glucose \<0.6\*LLN or \>1.5\*ULN, creatine kinase:\>3.0\*ULN); Urinalysis (Urine WBC and RBC: greater than or equal to \[\>=\] 6/High Power Field \[HPF\]).

    Time frame: Baseline up to Day 5

  4. Number of Participants With Clinically Significant Vital Signs Abnormalities

    Criteria for vital signs of potentially clinical concern included supine/sitting pulse rate of \<40 beats per minute (bpm) or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, systolic blood pressure of \>=30 millimeters of mercury (mmHg) change from baseline and systolic blood pressure \<90 mmHg, diastolic blood pressure \>=20 mmHg change from baseline and diastolic blood pressure \<50 mm Hg.

    Time frame: Baseline up to Day 5

Secondary outcomes

  1. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

    Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose

  4. Apparent Volume of Distribution (Vz/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose

  5. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose

  6. Taste Assessment

    Participants were evaluated for taste assessment using a 5 categories questionnaire. Participants were asked to answer one of the following to describe the taste of oral solution of tofacitinib: Dislike very much, dislike a little, not sure, like a little, or like very much. The taste assessment was only performed for participants who received the oral solution. Number of participants within each category are reported.

    Time frame: Day 1, Day 5

07

Results

Posted Jul 4, 2016

Participant flow

Participant flow — Overall Study
MilestoneCohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
Started899
Completed899
Not completed000

Outcome measures

PrimaryApparent Oral Clearance (CL/F)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is also influenced by the fraction of the dose absorbed. Clearance was estimated by non compartmental analysis (NCA) of PK data. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing the given oral dose by AUCtau. AUCtau is the area under the plasma concentration time-curve from time zero to end of dosing interval.

Time frame:
Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Reported as:
Geometric mean · liter per hour
Apparent Oral Clearance (CL/F)
liter per hourCohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
Apparent Oral Clearance (CL/F)28.09 ± 2225.48 ± 4020.53 ± 33
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) All Causalities

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs included both serious and non-serious AEs.

Time frame:
Baseline up to 28 days after the last dose of study drug (Day 5)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) All Causalities
participantsCohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
AE112
SAE000
PrimaryNumber of Participants With Laboratory Test Abnormalities

Participants with laboratory test abnormalities of potential clinical concern without regard to baseline abnormality were reported. Criteria: Hematology(hemoglobin,hematocrit,red blood cell\[RBC\] count:\<0.8\*lower limit of normal \[LLN\], platelets:\<0.5\*LLN/greater than \[\>\]1.75\*upper limit of normal\[ULN\], white blood cell \[WBC\] count:\<0.6\*LLN\>\</0\>1.5\*ULN, lymphocytes, total neutrophils:\<0.8\*LLN or \>1.2\*ULN, basophils, eosinophil, monocytes:\>1.2\*ULN); Liver Function (total bilirubin: \>1.5\*ULN, aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:\>3.0\*ULN, total protein, albumin:\<0.8\*LLN or \>1.2\*ULN);Renal Function (blood urea nitrogen, creatinine:\>1.3\*ULN, uric acid:\>1.2\*ULN); Electrolytes (sodium:\<0.95\*LLN or \>1.05\*ULN,potassium,chloride,calcium,bicarbonate:\<0.9\*LLN or \>1.1\*ULN);Clinical chemistry (glucose \<0.6\*LLN or \>1.5\*ULN, creatine kinase:\>3.0\*ULN); Urinalysis (Urine WBC and RBC: greater than or equal to \[\>=\] 6/High Power Field \[HPF\]).

Time frame:
Baseline up to Day 5
Reported as:
Number · participants
Number of Participants With Laboratory Test Abnormalities
participantsCohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
Number of Participants With Laboratory Test Abnormalities315
PrimaryNumber of Participants With Clinically Significant Vital Signs Abnormalities

Criteria for vital signs of potentially clinical concern included supine/sitting pulse rate of \<40 beats per minute (bpm) or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, systolic blood pressure of \>=30 millimeters of mercury (mmHg) change from baseline and systolic blood pressure \<90 mmHg, diastolic blood pressure \>=20 mmHg change from baseline and diastolic blood pressure \<50 mm Hg.

Time frame:
Baseline up to Day 5
Reported as:
Number · participants
Number of Participants With Clinically Significant Vital Signs Abnormalities
participantsCohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
Number of Participants With Clinically Significant Vital Signs Abnormalities000
SecondaryArea Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
Time frame:
Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
nanogram*hour per milliliter (ng*hr/mL)Cohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)156.6 ± 25118.8 ± 27142.5 ± 32
SecondaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax)
nanogram per milliliter (ng/mL)Cohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
Maximum Observed Plasma Concentration (Cmax)46.97 ± 4041.67 ± 2966.15 ± 28
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hoursCohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
Time to Reach Maximum Observed Plasma Concentration (Tmax)0.750 ± 251.00 ± 270.500 ± 32
SecondaryApparent Volume of Distribution (Vz/F)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Reported as:
Geometric mean · liter
Apparent Volume of Distribution (Vz/F)
literCohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
Apparent Volume of Distribution (Vz/F)104.9 ± 3571.0 ± 4051.44 ± 34
SecondaryPlasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Day 5: Pre-dose, 0.5, 1, 2, 4, 8 hours post dose
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2)
hoursCohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
Plasma Decay Half-Life (t1/2)2.616 ± 0.4541.949 ± 0.2941.771 ± 0.406
SecondaryTaste Assessment

Participants were evaluated for taste assessment using a 5 categories questionnaire. Participants were asked to answer one of the following to describe the taste of oral solution of tofacitinib: Dislike very much, dislike a little, not sure, like a little, or like very much. The taste assessment was only performed for participants who received the oral solution. Number of participants within each category are reported.

Time frame:
Day 1, Day 5
Reported as:
Number · participants
Taste Assessment
participantsCohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
Day 1: Dislike very much0 ± 0.453501 ± 0.293961 ± 0.40634
Day 1: Dislike a little002
Day 1: Not sure111
Day 1: Like a little131
Day 1: Like very much024
Day 5: Dislike very much010
Day 5: Dislike a little103
Day 5: Not sure121
Day 5: Like a little022
Day 5: Like very much023

Adverse events

Collected over Baseline up to 28 days after the last dose of study drug (Day 5). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort I: 12 Years to <18 Years—0/8 (0%)1/8 (12.5%)
Cohort II: 6 Years to <12 Years—0/9 (0%)1/9 (11.1%)
Cohort III: 2 Years to <6 Years—0/9 (0%)2/9 (22.2%)
Most frequent other events
Most frequent other events
EventCohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 Years
FatigueGeneral disorders1/80/90/9
AnaemiaBlood and lymphatic system disorders0/81/90/9
Viral infectionInfections and infestations0/80/91/9
BlisterSkin and subcutaneous tissue disorders0/80/91/9

Baseline characteristics

The safety analysis population included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 YearsTotal
Mean14.1 ± 2.09.4 ± 1.84.0 ± 1.09.0 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Cohort I: 12 Years to <18 YearsCohort II: 6 Years to <12 YearsCohort III: 2 Years to <6 YearsTotal
Female55717
Male3429
08

Study locations

10 sites
  • Explorer Clinic, University of Minnesota Children's Hospital
    Minneapolis, Minnesota 55454, United States
  • Clinical and Translational Science Institute Masonic Clinical Research Unit (Administration Only)
    Minneapolis, Minnesota 55455, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Randall Children's Hospital at Legacy Emanuel
    Portland, Oregon 97227, United States
  • PRI - Pediatric Rheumatology Research Institute GmbH
    Bad Bramstedt, 24576, Germany
  • Hamburger Zentrum fuer Kinder-und Jugendrheumatologie SchoenKlinik Hamburg Eilbek
    Hamburg, 22081, Germany
  • Asklepios Klinik Sankt Augustin Gmbh
    St. Augustin, 53757, Germany
  • Wojewodzki Specjalistyczny Szpital Dzieciecy im. Sw. Ludwika w Krakowie
    Krakow, 31-503, Poland
  • Klinika Kardiologii i Reumatologii Dzieciecej
    Lodz, 91-738, Poland
  • Narodny ustav reumatickych chorob
    Piestany, 921 12, Slovakia
09

References and documents

Publications

  • Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, Horneff G, Smolewska E, Vehe RK, Hazra A, Wang R, Mebus CA, Alvey C, Lamba M, Krishnaswami S, Stock TC, Wang M, Suehiro R, Martini A, Lovell DJ; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J. 2017 Dec 28;15(1):86. doi: 10.1186/s12969-017-0212-y. PubMed 29282090 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2012
First posted
Jan 20, 2012
Start
Mar 2013
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Jul 4, 2016
Last update
Jul 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01513902
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 20, 2012
Start date
Mar 2013
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Jul 4, 2016
Last update
Jul 4, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion